Candidiasis

Essentials of Clinical Mycology: Second Edition

Volumn , Issue , 2011, Pages 167-206

  Vazquez, Jose A ^a   Sobel, Jack D ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84878090149     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4419-6640-7_11     Document Type: Chapter

References (386)

1. Berkhout CM. De Schimmelgeschlachter Monilia, Oidium, Vospora, en Torula.; 1923.
2. Odds FC. Ecology of Candida and epidemiology of candidosis. In: Odds FC, editor. Candida and Candidosis. 2nd ed. London: Bailliere Tindall; 1988.
3. Pfaller MA, Diekema DJ, Jones RN, et al. International surveillanceof bloodstream infections due to Candida species: Frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program. J Clin Microbiol. 2001;39:3254-9.
4. Fidel Jr. PL, Vazquez JA, Sobel JD. Candida glabrata: review of epidemiology, pathogenesis, and clinical disease with comparison to C. albicans. Clin Microbiol Rev. 1999;12:80-96.
5. Gumbo T, Isada CM, Hall G, Karafa MT, Gordon SM. Candida glabrata Fungemia. Clinical features of 139 patients. Medicine (Baltimore). 1999;78:220-7.
6. Pfaller MA, Diekema DJ, Rinaldi MG, et al. Results from the ARTEMIS DISK Global Antifungal Surveillance Study: A 6.5-year analysis of susceptibilities of Candida and other yeast species to fluconazole and voriconazole by standardized disk diffusion testing. J Clin Microbiol. 2005;43:5848-59.
7. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: A persistent public health problem. Clin Microbiol Rev. 2007;20:133-63.
8. Girmenia C, Martino P, De Bernardis F, et al. Rising incidence of Candida parapsilosis fungemia in patients with hematologic malignancies: clinical aspects, predisposing factors, and differential pathogenicity of the causative strains. Clin Infect Dis. 1996;23:506-14.
9. Levy I, Rubin LG, Vasishtha S, Tucci V, Sood SK. Emergence of Candida parapsilosis as the predominant species causing candidemia in children. Clin Infect Dis. 1998;26:1086-8.
10. Sanchez V, Vazquez JA, Barth-Jones D, Dembry L, Sobel JD, Zervos MJ. Nosocomial acquisition of Candida parapsilosis: An epidemiologic study. Am J Med. 1993;94:577-82.
11. Kontoyiannis DP, Vaziri I, Hanna HA, et al. Risk factors for Candida tropicalis fungemia in patients with cancer. Clin Infect Dis. 2001;33:1676-81.
12. Merz WG, Karp JE, Schron D, Saral R. Increased incidence of fungemia caused by Candida krusei. J Clin Microbiol. 1986;24:581-4.
13. Wingard JR, Merz WG, Rinaldi MG, Johnson TR, Karp JE, Saral R. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med. 1991;325:1274-7.
14. Abbas J, Bodey GP, Hanna HA. Candida krusei fungemia. An escalating serious infection in immunocompromised patients. Arch Intern Med. 2000;160:2659-64.
15. Vazquez JA, Lundstrom T, Dembry L, et al. Invasive Candida guilliermondii infection: In vitro susceptibility studies and molecular analysis. Bone Marrow Transplant. 1995;16:849-53.
16. Yoon SA, Vazquez JA, Steffan PE, Sobel JD, Akins RA. Highfrequency, in vitro reversible switching of Candida lusitaniae clinical isolates from amphotericin B susceptibility to resistance. Antimicrob Agents Chemother. 1999;43:836-45.
17. Sanchez V, Vazquez JA, Barth-Jones D, Dembry L, Sobel JD, Zervos MJ. Epidemiology of nosocomial acquisition of Candida lusitaniae. J Clin Microbiol. 1992;30:3005-8.
18. Kwon-Chung KJ, Riggsby WS, Uphoff RA, et al. Genetic differences between type I and type II Candida stellatoidea. Infect Immun. 1989;57:527-32.
19. Kwon-Chung KJ, Wickes BL, Merz WG. Association of electrophoretic karyotype of Candida stellatoidea with virulence for mice. Infect Immun. 1988;56:1814-9.
20. Sullivan D, Coleman D. Candida dubliniensis: characteristics and identification. J Clin Microbiol. 1998;36:329-34.
21. Hidalgo JA, Brown W, Vazquez JA. Invasive Candida dubliniensis in an HIV-negative patient: A new opportunistic fungal pathogen. Infect Dis Clin Pract. 2000;9:176-9.
22. Sebti A, Kiehn TE, Perlin D, et al. Candida dubliniensis at a cancer center. Clin Infect Dis. 2001;32:1034-8.
23. Jabra-Rizk MA, Baqui AA, Kelley JI, Falkler Jr. WA, Merz WG, Meiller TF. Identification of Candida dubliniensis in a prospective study of patients in the United States. J Clin Microbiol. 1999;37:321-6.
24. Minces LR, Ho KS, Veldkamp PJ, Clancy CJ. Candida rugosa: A distinctive emerging cause of candidaemia. A case report and review of the literature. Scand J Infect Dis. 2009;41:1-5.
25. Lockhart SR, Messer SA, Pfaller MA, Diekema DJ. Geographic distribution and antifungal susceptibility of the newly described species Candida orthopsilosis and Candida metapsilosis in comparison to the closely related species Candida parapsilosis. J Clin Microbiol. 2008;46:2659-64.
26. Borman AM, Petch R, Linton CJ, Palmer MD, Bridge PD, Johnson EM. Candida nivariensis, an emerging pathogenic fungus with multidrug resistance to antifungal agents. J Clin Microbiol. 2008;46:933-8.
27. Bishop JA, Chase N, Magill SS, Kurtzman CP, Fiandaca MJ, Merz WG. Candida bracarensis detected among isolates of Candida glabrata by peptide nucleic acid fluorescence in situ hybridization: Susceptibility data and documentation of presumed infection. J Clin Microbiol. 2008;46:443-6.
28. Lockhart SR, Messer SA, Pfaller MA, Diekema DJ. Identification and susceptibility profile of Candida fermentati from a worldwide collection of Candida guilliermondii clinical isolates. J Clin Microbiol. 2009;47:242-4.
29. Brown AJ, Gow NA. Regulatory networks controlling Candida albicans morphogenesis. Trends Microbiol. 1999;7:333-8.
30. Grubb SE, Murdoch C, Sudbery PE, Saville SP, Lopez-Ribot JL, Thornhill MH. Adhesion of Candida albicans to endothelial cells under physiological conditions of flow. Infect Immun. 2009;77:3872-8.
31. Lo HJ, Kohler JR, DiDomenico B, Loebenberg D, Cacciapuoti A, Fink GR. Nonfilamentous C. albicans mutants are avirulent. Cell. 1997;90:939-49.
32. Saville SP, Lazzell AL, Chaturvedi AK, Monteagudo C, Lopez- Ribot JL. Use of a genetically engineered strain to evaluate the pathogenic potential of yeast cell and filamentous forms during Candida albicans systemic infection in immunodeficient mice. Infect Immun. 2008;76:97-102.
33. Gow NA, Brown AJ, Odds FC. Fungal morphogenesis and host invasion. Curr Opin Microbiol. 2002;5:366-71.
34. Saville SP, Lazzell AL, Bryant AP, et al. Inhibition of filamentation can be used to treat disseminated candidiasis. Antimicrob Agents Chemother. 2006;50:3312-6.
35. Sundstrom P. Adhesins in Candida albicans. Curr Opin Microbiol. 1999;2:353-7.
36. Staab JF, Bradway SD, Fidel PL, Sundstrom P. Adhesive and mammalian transglutaminase substrate properties of Candida albicans Hwp1. Science. 1999;283:1535-8.
37. Grubb SE, Murdoch C, Sudbery PE, Saville SP, Lopez-Ribot JL, Thornhill MH. Candida albicans-endothelial cell interactions: A key step in the pathogenesis of systemic candidiasis. Infect Immun. 2008;76:4370-7.
38. Leidich SD, Ibrahim AS, Fu Y, et al. Cloning and disruption of caPLB1, a phospholipase B gene involved in the pathogenicity of Candida albicans. J Biol Chem. 1998;273:26078-86.
39. Staib F. Proteolysis and pathogenicity of Candida albicans strains. Mycopathol Mycol Appl. 1969;37:345-8.
40. Monod M, Togni G, Hube B, Sanglard D. Multiplicity of genes encoding secreted aspartic proteinases in Candida species. Mol Microbiol. 1994;13:357-68.
41. Ramage G, Saville SP, Thomas DP, Lopez-Ribot JL. Candida biofilms: An update. Eukaryot Cell. 2005;4:633-8.
42. Kojic EM, Darouiche RO. Candida infections of medical devices. Clin Microbiol Rev. 2004;17:255-67.
43. Zaoutis TE, Argon J, Chu J, Berlin JA, Walsh TJ, Feudtner C. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: A propensity analysis. Clin Infect Dis. 2005;41:1232-9.
44. Sandven P. Epidemiology of candidemia. Rev Iberoam Micol. 2000;17:73-81.
45. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: Analysis of 24, 179 cases from a prospective nationwide surveillance study. Clin Infect Dis. 2004;39:309-17.
46. Wenzel RP, Gennings C. Bloodstream infections due to Candida species in the intensive care unit: Identifying especially high-risk patients to determine prevention strategies. Clin Infect Dis. 2005;41 Suppl 6:S389-93.
47. Rentz AM, Halpern MT, Bowden R. The impact of candidemia on length of hospital stay, outcome, and overall cost of illness. Clin Infect Dis. 1998;27:781-8.
48. Trick WE, Fridkin SK, Edwards JR, Hajjeh RA, Gaynes RP. Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. Clin Infect Dis. 2002;35:627-30.
49. Hajjeh RA, Sofair AN, Harrison LH, et al. Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program. J Clin Microbiol. 2004;42:1519-27.
50. Hidron AI, Edwards JR, Patel J, et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: Annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006- 2007. Infect Control Hosp Epidemiol. 2008;29:996-1011.
51. Vincent JL, Anaissie E, Bruining H, et al. Epidemiology, diagnosis and treatment of systemic Candida infection in surgical patients under intensive care. Intensive Care Med. 1998;24:206-16.
52. Beck-Sague C, Jarvis WR. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Infections Surveillance System. J Infect Dis. 1993;167:1247-51.
53. Fridkin SK, Jarvis WR. Epidemiology of nosocomial fungal infections. Clin Microbiol Rev. 1996;9:499-511.
54. Abi-Said D, Anaissie E, Uzun O, Raad I, Pinzcowski H, Vartivarian S. The epidemiology of hematogenous candidiasis caused by different Candida species. Clin Infect Dis. 1997;24:1122-8.
55. Marr KA, Seidel K, Slavin MA, et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis- related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood. 2000;96:2055-61.
56. Horn DL, Neofytos D, Anaissie EJ, et al. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin Infect Dis. 2009;48:1695-703.
57. Hachem R, Hanna H, Kontoyiannis D, Jiang Y, Raad I. The changing epidemiology of invasive candidiasis: Candida glabrata and Candida krusei as the leading causes of candidemia in hematologic malignancy. Cancer. 2008;112:2493-9.
58. Arendrup MC, Fuursted K, Gahrn-Hansen B, et al. Seminational surveillance of fungemia in Denmark: notably high rates of fungemia and numbers of isolates with reduced azole susceptibility. J Clin Microbiol. 2005;43:4434-40.
59. Pappas PG, Rex JH, Lee J, et al. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis. 2003;37:634-43.
60. Playford EG, Marriott D, Nguyen Q, et al. Candidemia in nonneutropenic critically ill patients: risk factors for non-albicans Candida spp. Crit Care Med. 2008;36:2034-9.
61. Playford EG, Webster AC, Sorrell TC, Craig JC. Antifungal agents for preventing fungal infections in non-neutropenic critically ill and surgical patients: Systematic review and meta-analysis of randomized clinical trials. J Antimicrob Chemother. 2006;57:628-38.
62. Bross J, Talbot GH, Maislin G, Hurwitz S, Strom BL. Risk factors for nosocomial candidemia: A case-control study in adults without leukemia. Am J Med. 1989;87:614-20.
63. Pittet D, Monod M, Suter PM, Frenk E, Auckenthaler R. Candida colonization and subsequent infections in critically ill surgical patients. Ann Surg. 1994;220:751-8.
64. Blumberg HM, Jarvis WR, Soucie JM, et al. Risk factors for candidal bloodstream infections in surgical intensive care unit patients: The NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey. Clin Infect Dis. 2001;33:177-86.
65. Kao AS, Brandt ME, Pruitt WR, et al. The epidemiology of candidemia in two United States cities: results of a population-based active surveillance. Clin Infect Dis. 1999;29:1164-70.
66. Mahayni R, Vazquez JA, Zervos MJ. Nosocomial candidiasis: epidemiology and drug resistance. Infect Agents Dis. 1995;4:248-53.
67. Pfaller MA, Cabezudo I, Hollis R, Huston B, Wenzel RP. The use of biotyping and DNA fingerprinting in typing Candida albicans from hospitalized patients. Diagn Microbiol Infect Dis. 1990;13:481-9.
68. Vazquez JA, Sanchez V, Dmuchowski C, Dembry LM, Sobel JD, Zervos MJ. Nosocomial acquisition of Candida albicans: An epidemiologic study. J Infect Dis. 1993;168:195-201.
69. Vaudry WL, Tierney AJ, Wenman WM. Investigation of a cluster of systemic Candida albicans infections in a neonatal intensive care unit. J Infect Dis. 1988;158:1375-9.
70. Berger C, Frei R, Gratwohl A, Scheidegger C. Bottled lemon juice - A cryptic source of invasive Candida infections in the immunocompromised host. J Infect Dis. 1988;158:654-5.
71. Langenbeck B. Auffingung von Pilzer aus der Schleimhaut der Speiserohre einer Typhus-Leiche. Neu Not Geb. Nautur-u-Heilk (Froorief). 1939;12:145-7.
72. Berg FT. GM Torsk hos Barn. Stockholm: LJ Hjerta; 1846.
73. Villar CC, Dongari-Bagtzoglou A. Immune defence mechanisms and immunoenhancement strategies in oropharyngeal candidiasis. Expert Rev Mol Med. 2008;10:e29.
74. Sobel JD, Vazquez JA. Gastrointestinal and hepatic infections. In: Surawicz CM, editor. Fungal Infections of the Gastrointestinal Tract. Philadelphia: WB Saunders; 1995. p. 219-46.
75. Samonis G, Anaissie EJ, Rosenbaum B, Bodey GP. A model of sustained gastrointestinal colonization by Candida albicans in healthy adult mice. Infect Immun. 1990;58:1514-7.
76. Yeo E, Alvarado T, Fainstein V, Bodey GP. Prophylaxis of oropharyngeal candidiasis with clotrimazole. J Clin Oncol. 1985;3:1668-71.
77. Feigal DW, Katz MH, Greenspan D, et al. The prevalence of oral lesions in HIV-infected homosexual and bisexual men: Three San Francisco epidemiological cohorts. AIDS. 1991;5:519-25.
78. Klein RS, Harris CA, Small CB, Moll B, Lesser M, Friedland GH. Oral candidiasis in high-risk patients as the initial manifestation of the acquired immunodeficiency syndrome. N Engl J Med. 1984;311:354-8.
79. Lamey PJ, Lamb AB. Prospective study of aetiological factors in burning mouth syndrome. Br Med J (Clin Res Ed). 1988;296:1243-6.
80. Whelan WL, Delga JM, Wadsworth E, et al. Isolation and characterization of cell surface mutants of Candida albicans. Infect Immun. 1990;58:1552-7.
81. Mercante DE, Leigh JE, Lilly EA, McNulty K, Fidel Jr. PL. Assessment of the association between HIV viral load and CD4 cell count on the occurrence of oropharyngeal candidiasis in HIV-infected patients. J Acquir Immune Defic Syndr. 2006;42:578-83.
82. Delgado AC, de Jesus Pedro R, Aoki FH, et al. Clinical and microbiological assessment of patients with a long-term diagnosis of human immunodeficiency virus infection and Candida oral colonization. Clin Microbiol Infect. 2009;15:364-71.
83. Vazquez JA. Therapeutic options for the management of oropharyngeal and esophageal candidiasis in HIV/AIDS patients. HIV Clin Trials. 2000;1:47-59.
84. Barchiesi F, Morbiducci V, Ancarani F, Scalise G. Emergence of oropharyngeal candidiasis caused by non-albicans species of Candida in HIV-infected patients. Eur J Epidemiol. 1993;9:455-6.
85. Fidel PL, Lilly E, Rufener JB, et al. Longitudinal analysis of local immune function in HIV + subjects with oropharyngeal candidiasis. In: Annual Interscience Conference on Antimicrobial Agents and Chemotherapeutics; 2009 9/11-15/2009; San Francisco, 2009. p. Abstract M-365.
86. Letiner T. Oral thrush or acute pseudomembranous candidiasis: A clinical-pathologic study of 44 cases. Oral Surg. 1964;18:27-37.
87. Budtz-Jorgensen E, Stenderup A, Grabowski M. An epidemiologic study of yeasts in elderly denture wearers. Community Dent Oral Epidemiol. 1975;3:115-9.
88. Cernea P, Crepy C, Kuffer R, Mascaro JM, Badillet G, Marie JL. Little known aspects of oral condidiasis. The candidiasis with multiple foci of the oral cavity. Rev Stomatol Chir Maxillofac. 1965;66:103-38.
89. Wheeler RR, Peacock Jr. JE, Cruz JM, Richter JE. Esophagitis in the immunocompromised host: role of esophagoscopy in diagnosis. Rev Infect Dis. 1987;9:88-96.
90. Clotet B, Grifol M, Parra O, et al. Asymptomatic esophageal candidiasis in the acquired-immunodeficiency-syndrome-related complex. Ann Intern Med. 1986;105:145.
91. Kodsi BE, Wickremesinghe C, Kozinn PJ, Iswara K, Goldberg PK. Candida esophagitis: A prospective study of 27 cases. Gastroenterology. 1976;71:715-9.
92. Alteras I, Feuerman EJ, David M, Shohat B, Livni E. Widely disseminated cutaneous candidosis in adults. Sabouraudia. 1979;17:383-8.
93. Fitzpatrick TB, Johnson RA, Wolff K, Polano MK, Suurmond D. Color atlas and synopsis of clinical dermatology: Common and serious diseases. 3rd ed. New York: McGraw Hill; 1997.
94. Arbegast KD, Lamberty LF, Koh JK, Pergram JM, Braddock SW. Congenital candidiasis limited to the nail plates. Pediatr Dermatol. 1990;7:310-2.
95. Kirkpatrick CH. Chronic mucocutaneous candidiasis. J Am Acad Dermatol. 1994;31:S14-7.
96. Ahonen P, Myllarniemi S, Sipila I, Perheentupa J. Clinical variation of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) in a series of 68 patients. N Engl J Med. 1990;322:1829-36.
97. Bjorses P, Aaltonen J, Vikman A, et al. Genetic homogeneity of autoimmune polyglandular disease type I. Am J Hum Genet. 1996;59:879-86.
98. Hermans PE, Ritts Jr. RE. Chronic mucocutaneous candidiasis. Its association with immunologic and endocrine abnormalities. Minn Med. 1970;53:75-80.
99. Okamoto GA, Hall JG, Ochs H, Jackson C, Rodaway K, Chandler J. New syndrome of chronic mucocutaneous candidiasis. Birth Defects Orig Artic Ser. 1977;13:117-25.
100. Holt PJ, Higgs JM, Munro J, Valdimarsson H. Chronic mucocutaneous candidiasis: A model for the investigation of cell mediated immunity. Br J Clin Pract. 1972;26:331-6.
101. Durandy A, Fischer A, Le Deist F, Drouhet E, Griscelli C. Mannan-specific and mannan-induced T-cell suppressive activity in patients with chronic mucocutaneous candidiasis. J Clin Immunol. 1987;7:400-9.
102. Hurley R, DeLouvois J. Candida vaginitis. Postgrad Med J. 1979;55:645-7.
103. Sobel JD, Bradshaw SK, Lipka CJ, Kartsonis NA. Caspofungin in the treatment of symptomatic candiduria. Clin Infect Dis. 2007;44:e46-9.
104. Sobel JD. Vulvovaginal candidosis. Lancet. 2007;369:1961-71.
105. Witkin SS. Immunologic factors influencing susceptibility to recurrent candidal vaginitis. Clin Obstet Gynecol. 1991;34:662-8.
106. Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;48:503-35.
107. Berenguer J, Buck M, Witebsky F, Stock F, Pizzo PA, Walsh TJ. Lysis-centrifugation blood cultures in the detection of tissueproven invasive candidiasis. Disseminated versus single-organ infection. Diagn Microbiol Infect Dis. 1993;17:103-9.
108. Hockey LJ, Fujita NK, Gibson TR, Rotrosen D, Montgomerie JZ, Edwards Jr. JE. Detection of fungemia obscured by concomitant bacteremia: In vitro and in vivo studies. J Clin Microbiol. 1982;16:1080-5.
109. Lecciones JA, Lee JW, Navarro EE, et al. Vascular catheter-associated fungemia in patients with cancer: Analysis of 155 episodes. Clin Infect Dis. 1992;14:875-83.
110. Anaissie EJ, Rex JH, Uzun O, Vartivarian S. Predictors of adverse outcome in cancer patients with candidemia. Am J Med. 1998;104:238-45.
111. Wingard JR. Importance of Candida species other than C. albicans as pathogens in oncology patients. Clin Infect Dis. 1995;20:115-25.
112. Murray PR. Comparison of the lysis-centrifugation and agitated biphasic blood culture systems for detection of fungemia. J Clin Microbiol. 1991;29:96-8.
113. Wey SB, Mori M, Pfaller MA, Woolson RF, Wenzel RP. Hospitalacquired candidemia. The attributable mortality and excess length of stay. Arch Intern Med. 1988;148:2642-5.
114. Komshian SV, Uwaydah AK, Sobel JD, Crane LR. Fungemia caused by Candida species and Torulopsis glabrata in the hospitalized patient: Frequency, characteristics, and evaluation of factors influencing outcome. Rev Infect Dis. 1989;11:379-90.
115. Fraser VJ, Jones M, Dunkel J, Storfer S, Medoff G, Dunagan WC. Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality. Clin Infect Dis. 1992;15:414-21.
116. McNeil MM, Nash SL, Hajjeh RA, et al. Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997. Clin Infect Dis. 2001;33:641-7.
117. Edwards Jr. JE, Foos RY, Montgomerie JZ, Guze LB. Ocular manifestations of Candida septicemia: review of seventy-six cases of hematogenous Candida endophthalmitis. Medicine (Baltimore). 1974;53:47-75.
118. Samiy N, D'Amico DJ. Endogenous fungal endophthalmitis. Int Ophthalmol Clin. 1996;36:147-62.
119. Khan FA, Slain D, Khakoo RA. Candida endophthalmitis: Focus on current and future antifungal treatment options. Pharmacotherapy. 2007;27:1711-21.
120. Noyola DE, Fernandez M, Moylett EH, Baker CJ. Ophthalmologic, visceral, and cardiac involvement in neonates with candidemia. Clin Infect Dis. 2001;32:1018-23.
121. Brooks RG. Prospective study of Candida endophthalmitis in hospitalized patients with candidemia. Arch Intern Med. 1989;149:2226-8.
122. Krishna R, Amuh D, Lowder CY, Gordon SM, Adal KA, Hall G. Should all patients with candidaemia have an ophthalmic examination to rule out ocular candidiasis? Eye. 2000;14(Pt 1):30-4.
123. Joshi N, Hamory BH. Endophthalmitis caused by non-albicans species of Candida. Rev Infect Dis. 1991;13:281-7.
124. Henderson DK, Hockey LJ, Vukalcic LJ, Edwards Jr. JE. Effect of immunosuppression on the development of experimental hematogenous Candida endophthalmitis. Infect Immun. 1980;27:628-31.
125. McDonald HR, DeBustros S, Sipperley JO. Vitrectomy for epiretinal membrane with Candida chorioretinitis. Ophthalmology. 1990;97:466-9.
126. Franklin WG, Simon AB, Sodeman TM. Candida myocarditis without valvulitis. Am J Cardiol. 1976;38:924-8.
127. Rubin RH, Moellering Jr. RC. Clinical, microbiologic and therapeutic aspects of purulent pericarditis. Am J Med. 1975;59:68-78.
128. Schrank Jr. JH, Dooley DP. Purulent pericarditis caused by Candida species: case report and review. Clin Infect Dis. 1995;21:182-7.
129. Rubinstein E, Noriega ER, Simberkoff MS, Holzman R, Rahal Jr. JJ. Fungal endocarditis: Analysis of 24 cases and review of the literature. Medicine (Baltimore). 1975;54:331-4.
130. Ellis ME, Al-Abdely H, Sandridge A, Greer W, Ventura W. Fungal endocarditis: evidence in the world literature, 1965-1995. Clin Infect Dis. 2001;32:50-62.
131. Chim CS, Ho PL, Yuen ST, Yuen KY. Fungal endocarditis in bone marrow transplantation: case report and review of literature. J Infect. 1998;37:287-91.
132. Nasser RM, Melgar GR, Longworth DL, Gordon SM. Incidence and risk of developing fungal prosthetic valve endocarditis after nosocomial candidemia. Am J Med. 1997;103:25-32.
133. Joly V, Belmatoug N, Leperre A, et al. Pacemaker endocarditis due to Candida albicans: case report and review. Clin Infect Dis. 1997;25:1359-62.
134. Galgiani JN, Stevens DA. Fungal endocarditis: need for guidelines in evaluating therapy. Experience with two patients previously reported. J Thorac Cardiovasc Surg. 1977;73:293-6.
135. Friedland IR. Peripheral thrombophlebitis caused by Candida. Pediatr Infect Dis J. 1996;15:375-7.
136. Khan EA, Correa AG, Baker CJ. Suppurative thrombophlebitis in children: A ten-year experience. Pediatr Infect Dis J. 1997;16:63-7.
137. Walsh TJ, Bustamente CI, Vlahov D, Standiford HC. Candidal suppurative peripheral thrombophlebitis: recognition, prevention, and management. Infect Control. 1986;7:16-22.
138. Doscher W, Krishnasastry KV, Deckoff SL. Fungal graft infections: case report and review of the literature. J Vasc Surg. 1987;6:398-402.
139. Gorg C, Weide R, Schwerk WB, Koppler H, Havemann K. Ultrasound evaluation of hepatic and splenic microabscesses in the immunocompromised patient: Sonographic patterns, differential diagnosis, and follow-up. J Clin Ultrasound. 1994;22:525-9.
140. Anttila VJ, Ruutu P, Bondestam S, et al. Hepatosplenic yeast infection in patients with acute leukemia: A diagnostic problem. Clin Infect Dis. 1994;18:979-81.
141. Semelka RC, Shoenut JP, Greenberg HM, Bow EJ. Detection of acute and treated lesions of hepatosplenic candidiasis: comparison of dynamic contrast-enhanced CT and MR imaging. J Magn Reson Imaging. 1992;2:341-5.
142. Faix RG. Invasive neonatal candidiasis: comparison of albicans and parapsilosis infection. Pediatr Infect Dis J. 1992;11:88-93.
143. Jin Y, Endo A, Shimada M, et al. Congenital systemic candidiasis. Pediatr Infect Dis J. 1995;14:818-20.
144. Almeida Santos L, Beceiro J, Hernandez R, et al. Congenital cutaneous candidiasis: report of four cases and review of the literature. Eur J Pediatr. 1991;150:336-8.
145. Glassman BD, Muglia JJ. Widespread erythroderma and desquamation in a neonate. Congenital cutaneous candidiasis (CCC). Arch Dermatol. 1993;129:899-902.
146. Barone SR, Krilov LR. Neonatal candidal meningitis in a fullterm infant with congenital cutaneous candidiasis. Clin Pediatr (Phila). 1995;34:217-9.
147. Lipton SA, Hickey WF, Morris JH, Loscalzo J. Candidal infection in the central nervous system. Am J Med. 1984;76:101-8.
148. Petraitiene R, Petraitis V, Hope WW, et al. Cerebrospinal fluid and plasma (1- > 3)-beta-D-glucan as surrogate markers for detection and monitoring of therapeutic response in experimental hematogenous Candida meningoencephalitis. Antimicrob Agents Chemother. 2008;52:4121-9.
149. Treseler CB, Sugar AM. Fungal meningitis. Infect Dis Clin North Am. 1990;4:789-808.
150. Voice RA, Bradley SF, Sangeorzan JA, Kauffman CA. Chronic candidal meningitis: An uncommon manifestation of candidiasis. Clin Infect Dis. 1994;19:60-6.
151. Burgert SJ, Classen DC, Burke JP, Blatter DD. Candidal brain abscess associated with vascular invasion: A devastating complication of vascular catheter-related candidemia. Clin Infect Dis. 1995;21:202-5.
152. Lai PH, Lin SM, Pan HB, Yang CF. Disseminated miliary cerebral candidiasis. AJNR Am J Neuroradiol. 1997;18:1303-6.
153. McCullers JA, Vargas SL, Flynn PM, Razzouk BI, Shenep JL. Candidal meningitis in children with cancer. Clin Infect Dis. 2000;31:451-7.
154. Fernandez M, Moylett EH, Noyola DE, Baker CJ. Candidal meningitis in neonates: A 10-year review. Clin Infect Dis. 2000;31:458-63.
155. Nguyen MH, Yu VL. Meningitis caused by Candida species: An emerging problem in neurosurgical patients. Clin Infect Dis. 1995;21:323-7.
156. Gower DJ, Crone K, Alexander Jr. E, Kelly Jr. DL. Candida albicans shunt infection: report of two cases. Neurosurgery. 1986;19:111-3.
157. Chmel H. Candida albicans meningitis following lumbar puncture. Am J Med Sci. 1973;266:465-7.
158. Masur H, Rosen PP, Armstrong D. Pulmonary disease caused by Candida species. Am J Med. 1977;63:914-25.
159. Haron E, Vartivarian S, Anaissie E, Dekmezian R, Bodey GP. Primary Candida pneumonia. Experience at a large cancer center and review of the literature. Medicine (Baltimore). 1993;72:137-42.
160. Heurlin N, Bergstrom SE, Winiarski J, et al. Fungal pneumonia: The predominant lung infection causing death in children undergoing bone marrow transplantation. Acta Paediatr. 1996;85:168-72.
161. Zeluff BJ. Fungal pneumonia in transplant recipients. Semin Respir Infect. 1990;5:80-9.
162. Lee TM, Greenberger PA, Oh S, Patterson R, Roberts M, Liotta JL. Allergic bronchopulmonary candidiasis: case report and suggested diagnostic criteria. J Allergy Clin Immunol. 1987;80:816-20.
163. von Eiff M, Zuhlsdorf M, Roos N, Hesse M, Schulten R, van de Loo J. Pulmonary fungal infections in patients with hematological malignancies - diagnostic approaches. Ann Hematol. 1995; 70:135-41.
164. el-Ebiary M, Torres A, Fabregas N, et al. Significance of the isolation of Candida species from respiratory samples in critically ill, non-neutropenic patients. An immediate postmortem histologic study. Am J Respir Crit Care Med. 1997;156:583-90.
165. Walsh TJ, Gray WC. Candida epiglottitis in immunocompromised patients. Chest. 1987;91:482-5.
166. Michigan S. Genitourinary fungal infections. J Urol. 1976;116:390-7.
167. Febre N, Silva V, Medeiros EA, Wey SB, Colombo AL, Fischman O. Microbiological characteristics of yeasts isolated from urinary tracts of intensive care unit patients undergoing urinary catheterization. J Clin Microbiol. 1999;37:1584-6.
168. Fisher JF, Chew WH, Shadomy S, Duma RJ, Mayhall CG, House WC. Urinary tract infections due to Candida albicans. Rev Infect Dis. 1982;4:1107-18.
169. Kauffman CA, Vazquez JA, Sobel JD, et al. Prospective multicenter surveillance study of funguria in hospitalized patients. The National Institute for Allergy and Infectious Diseases (NIAID) Mycoses Study Group. Clin Infect Dis. 2000;30:14-8.
170. Safdar N, Slattery WR, Knasinski V, et al. Predictors and outcomes of candiduria in renal transplant recipients. Clin Infect Dis. 2005;40:1413-21.
171. Sobel JD, Kauffman CA, McKinsey D, et al. Candiduria: A randomized, double-blind study of treatment with fluconazole and placebo. The National Institute of Allergy and Infectious Diseases (NIAID) Mycoses Study Group. Clin Infect Dis. 2000;30:19-24.
172. Kozinn PJ, Taschdjian CL, Goldberg PK, Wise GJ, Toni EF, Seelig MS. Advances in the diagnosis of renal candidiasis. J Urol. 1978;119:184-7.
173. Stone HH, Kolb LD, Currie CA, Geheber CE, Cuzzell JZ. Candida sepsis: Pathogenesis and principles of treatments. Ann Surg. 1974;179:697-711.
174. Calandra T, Bille J, Schneider R, Mosimann F, Francioli P. Clinical significance of Candida isolated from peritoneum in surgical patients. Lancet. 1989;2:1437-40.
175. Benedetti E, Gruessner AC, Troppmann C, et al. Intra-abdominal fungal infections after pancreatic transplantation: Incidence, treatment, and outcome. J Am Coll Surg. 1996;183:307-16.
176. Peoples JB. Candida and perforated peptic ulcers. Surgery. 1986;100:758-64.
177. Eggimann P, Francioli P, Bille J, et al. Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients. Crit Care Med. 1999;27:1066-72.
178. Rubin J, Kirchner K, Walsh D, Green M, Bower J. Fungal peritonitis during continuous ambulatory peritoneal dialysis: A report of 17 cases. Am J Kidney Dis. 1987;10:361-8.
179. Goldie SJ, Kiernan-Tridle L, Torres C, et al. Fungal peritonitis in a large chronic peritoneal dialysis population: A report of 55 episodes. Am J Kidney Dis. 1996;28:86-91.
180. Ehrenstein BP, Salamon L, Linde HJ, Messmann H, Scholmerich J, Gluck T. Clinical determinants for the recovery of fungal and mezlocillin-resistant pathogens from bile specimens. Clin Infect Dis. 2002;34:902-8.
181. Morris AB, Sands ML, Shiraki M, Brown RB, Ryczak M. Gallbladder and biliary tract candidiasis: nine cases and review. Rev Infect Dis. 1990;12:483-9.
182. Clancy CJ, Nguyen MH, Morris AJ. Candidal mediastinitis: An emerging clinical entity. Clin Infect Dis. 1997;25:608-13.
183. Hendrickx L, Van Wijngaerden E, Samson I, Peetermans WE. Candidal vertebral osteomyelitis: report of 6 patients, and a review. Clin Infect Dis. 2001;32:527-33.
184. Hansen BL, Andersen K. Fungal arthritis. A review. Scand J Rheumatol. 1995;24:248-50.
185. Fukasawa N, Shirakura K. Candida arthritis after total knee arthroplasty - A case of successful treatment without prosthesis removal. Acta Orthop Scand. 1997;68:306-7.
186. Belzunegui J, Gonzalez C, Lopez L, Plazaola I, Maiz O, Figueroa M. Osteoarticular and muscle infectious lesions in patients with the human immunodeficiency virus. Clin Rheumatol. 1997;16:450-3.
187. Rowen JL, Tate JM, Nordoff N, Passarell L, McGinnis MR. Candida isolates from neonates: Frequency of misidentification and reduced fluconazole susceptibility. J Clin Microbiol. 1999;37:3735-7.
188. Wilson ML, Davis TE, Mirrett S, et al. Controlled comparison of the BACTEC high-blood-volume fungal medium, BACTEC Plus 26 aerobic blood culture bottle, and 10-milliliter isolator blood culture system for detection of fungemia and bacteremia. J Clin Microbiol. 1993;31:865-71.
189. Obayashi T, Yoshida M, Mori T, et al. Plasma (1- > 3)-beta-Dglucan measurement in diagnosis of invasive deep mycosis and fungal febrile episodes. Lancet. 1995;345:17-20.
190. Ostrosky-Zeichner L, Alexander BD, Kett DH, et al. Multicenter clinical evaluation of the (1- > 3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis. 2005;41:654-9.
191. Nett J, Lincoln L, Marchillo K, Andes D. Beta-1, 3 glucan as a test for central venous catheter biofilm infection. J Infect Dis. 2007;195:1705-12.
192. Rigby S, Procop GW, Haase G, et al. Fluorescence in situ hybridization with peptide nucleic acid probes for rapid identification of Candida albicans directly from blood culture bottles. J Clin Microbiol. 2002;40:2182-6.
193. Wilson DA, Joyce MJ, Hall LS, et al. Multicenter evaluation of a Candida albicans peptide nucleic acid fluorescent in situ hybridization probe for characterization of yeast isolates from blood cultures. J Clin Microbiol. 2005;43:2909-12.
194. Shepard JR, Addison RM, Alexander BD, et al. Multicenter evaluation of the Candida albicans/Candida glabrata peptide nucleic acid fluorescent in situ hybridization method for simultaneous dual-color identification of C. albicans and C. glabrata directly from blood culture bottles. J Clin Microbiol. 2008;46:50-5.
195. Gherna M, Merz WG. Identification of Candida albicans and Candida glabrata within 1.5 hours directly from positive blood culture bottles with a shortened peptide nucleic acid fluorescence in situ hybridization protocol. J Clin Microbiol. 2009;47:247-8.
196. NCCLS. Reference method for broth dilution antifungal susceptibility testing of yeasts. Document M27-A. Wayne: NCCLS, 1997.
197. Kurtz MB, Rex JH. Glucan synthase inhibitors as antifungal agents. Adv Protein Chem. 2001;56:423-75.
198. Rex JH, Pfaller MA, Galgiani JN, et al. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards. Clin Infect Dis. 1997;24:235-47.
199. Chow JK, Golan Y, Ruthazer R, et al. Factors associated with candidemia caused by non-albicans Candida species versus Candida albicans in the intensive care unit. Clin Infect Dis. 2008;46:1206-13.
200. Sobel JD, Revankar SG, Vazquez J, Ostrosky-Zeichner L. Mucocutaenous candidiasis in guidelines for prevention and treatment of opportunistic infections in HIV-infected adult and adolescents. MMWR Morb Mortal Wkly Rep. 2008;57:46-9.
201. Kozinn PJ, Taschdjian CL, Dragutsky D. Therapy of oral thrush: A comparative ealuation of gentian violet, mycostatin, and amphotericin B. Monogr Ther. 1957;2:16-24.
202. Shechtman LB, Funaro L, Robin T, Bottone EJ, Cuttner J. Clotrimazole treatment of oral candidiasis in patients with neoplastic disease. Am J Med. 1984;76:91-4.
203. Hughes WT, Bartley DL, Patterson GG, Tufenkeji H. Ketoconazole and candidiasis: A controlled study. J Infect Dis. 1983;147:1060-3.
204. Vazquez JA, Epstein J, Attali P. A multicenter, randomized trial evaluating the efficacy and safety of miconazole mucoadhesive buccal Tablets (MMBT) versus clotrimazole troches (CT) for the treatment of oropharyngeal candidiasis (OPC) in subjects with HIV/AIDS: SMiLES Trial. In: 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapeutics; Sept 11-15, 2009; San Francisco; 2009.
205. Cardot JM, Chaumont C, Dubray C, Costantini D, Aiache JM. Comparison of the pharmacokinetics of miconazole after administration via a bioadhesive slow release tablet and an oral gel to healthy male and female subjects. Br J Clin Pharmacol. 2004;58:345-51.
206. Hay RJ. Overview of studies of fluconazole in oropharyngeal candidiasis. Rev Infect Dis. 1990;12 Suppl 3:S334-7.
207. Vazquez JA, Skiest DJ, Nieto L, et al. A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS. Clin Infect Dis. 2006;42:1179-86.
208. Skiest DJ, Vazquez JA, Anstead GM, et al. Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection. Clin Infect Dis. 2007;44:607-14.
209. Meunier-Carpentier F, Cruciani M, Klastersky J. Oral prophylaxis with miconazole or ketoconazole of invasive fungal disease in neutropenic cancer patients. Eur J Cancer Clin Oncol. 1983;19:43-8.
210. Fazio RA, Wickremesinghe PC, Arsura EL. Ketoconazole treatment of Candida esophagitis - A prospective study of 12 cases. Am J Gastroenterol. 1983;78:261-4.
211. Wilcox CM, Darouiche RO, Laine L, Moskovitz BL, Mallegol I, Wu J. A randomized, double-blind comparison of itraconazole oral solution and fluconazole tablets in the treatment of esophageal candidiasis. J Infect Dis. 1997;176:227-32.
212. Vazquez JA, Skiest DJ, Tissot-Dupont H, Lennox JL, Boparai N, Isaacs R. Safety and efficacy of posaconazole in the long-term treatment of azole-refractory oropharyngeal and esophageal candidiasis in patients with HIV infection. HIV Clin Trials. 2007;8:86-97.
213. Maenza JR, Keruly JC, Moore RD, Chaisson RE, Merz WG, Gallant JE. Risk factors for fluconazole-resistant candidiasis in human immunodeficiency virus-infected patients. J Infect Dis. 1996;173:219-25.
214. Maenza JR, Merz WG, Romagnoli MJ, Keruly JC, Moore RD, Gallant JE. Infection due to fluconazole-resistant Candida in patients with AIDS: Prevalence and microbiology. Clin Infect Dis. 1997;24:28-34.
215. Ally R, Schurmann D, Kreisel W, et al. A randomized, doubleblind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin Infect Dis. 2001;33:1447-54.
216. Villanueva A, Arathoon EG, Gotuzzo E, Berman RS, DiNubile MJ, Sable CA. A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis. Clin Infect Dis. 2001;33:1529-35.
217. Krause DS, Simjee AE, van Rensburg C, et al. A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis. Clin Infect Dis. 2004;39:770-5.
218. de Wet NT, Bester AJ, Viljoen JJ, et al. A randomized, double blind, comparative trial of micafungin (FK463) vs. fluconazole for the treatment of oesophageal candidiasis. Aliment Pharmacol Ther. 2005;21:899-907.
219. Medoff G, Dismukes WE, Meade 3rd RH, Moses JM. A new therapeutic approach to Candida infections. A preliminary report. Arch Intern Med. 1972;130:241-5.
220. Koletar SL, Weed HG, Raimundo MB. Thrush unresponsive to treatment with fluconazole in HIV-infected patients. In: First National Conference on Human Retroviruses; 1994; Washington, DC; 1994.
221. Cameron ML, Schell WA, Bruch S, Bartlett JA, Waskin HA, Perfect JR. Correlation of in vitro fluconazole resistance of Candida isolates in relation to therapy and symptoms of individuals seropositive for human immunodeficiency virus type 1. Antimicrob Agents Chemother. 1993;37:2449-53.
222. Quereda C, Polanco AM, Giner C, et al. Correlation between in vitro resistance to fluconazole and clinical outcome of oropharyngeal candidiasis in HIV-infected patients. Eur J Clin Microbiol Infect Dis. 1996;15:30-7.
223. Martins MD, Rex JH. Fluconazole suspension for oropharyngeal candidiasis unresponsive to tablets. Ann Intern Med. 1997;126:332-3.
224. Eichel M, Just-Nubling G, Helm EB, Stille W. Itraconazole suspension in the treatment of HIV-infected patients with fluconazole- resistant oropharyngeal candidiasis and esophagitis. Mycoses. 1996;39 Suppl 1:102-6.
225. Cartledge JD, Midgley J, Gazzard BG. Itraconazole cyclodextrin solution: The role of in vitro susceptibility testing in predicting successful treatment of HIV-related fluconazole-resistant and fluconazole- susceptible oral candidosis. AIDS. 1997;11:163-8.
226. Nguyen MT, Weiss PJ, LaBarre RC, Miller LK, Oldfield EC, Wallace MR. Orally administered amphotericin B in the treatment of oral candidiasis in HIV-infected patients caused by azole-resistant Candida albicans. AIDS. 1996;10:1745-7.
227. Ruhnke M, Schmidt-Westhausen A, Trautmann M. In vitro activities of voriconazole (UK-109, 496) against fluconazole-susceptible and -resistant Candida albicans isolates from oral cavities of patients with human immunodeficiency virus infection. Antimicrob Agents Chemother. 1997;41:575-7.
228. Vazquez JA, Schranz JA, Clark K, Goldstein BP, Reboli A, Fichtenbaum C. A phase 2, open-label study of the safety and efficacy of intravenous anidulafungin as a treatment for azole-refractory mucosal candidiasis. J Acquir Immune Defic Syndr. 2008;48:304-9.
229. Brajtburg J, Powderly WG, Kobayashi GS, Medoff G. Amphotericin B: delivery systems. Antimicrob Agents Chemother. 1990;34:381-4.
230. Zingman BS. Resolution of refractory AIDS-related mucosal candidiasis after initiation of didanosine plus saquinavir. N Engl J Med. 1996;334:1674-5.
231. Swindells S. Pilot study of adjunctive GM-CSF (yeast derived) for fluconazole-resistant oral candidiasis in HIV-infection. Infect Dis Clin Pract. 1997;6:278-9.
232. Powderly WG, Finkelstein D, Feinberg J, et al. A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group. N Engl J Med. 1995;332:700-5.
233. Schuman P, Capps L, Peng G, et al. Weekly fluconazole for the prevention of mucosal candidiasis in women with HIV infection. A randomized, double-blind, placebo-controlled trial. Terry Beirn Community Programs for Clinical Research on AIDS. Ann Intern Med. 1997;126:689-96.
234. Philpott-Howard JN, Wade JJ, Mufti GJ, Brammer KW, Ehninger G. Randomized comparison of oral fluconazole versus oral polyenes for the prevention of fungal infection in patients at risk of neutropenia. Multicentre Study Group. J Antimicrob Chemother. 1993;31:973-84.
235. Goldman M, Cloud GA, Wade KD, et al. A randomized study of the use of fluconazole in continuous versus episodic therapy in patients with advanced HIV infection and a history of oropharyngeal candidiasis: AIDS Clinical Trials Group Study 323/Mycoses Study Group Study 40. Clin Infect Dis. 2005;41:1473-80.
236. Sobel JD, Brooker D, Stein GE, et al. Single oral dose fluconazole compared with conventional clotrimazole topical therapy of Candida vaginitis. Fluconazole Vaginitis Study Group. Am J Obstet Gynecol. 1995;172:1263-8.
237. Nurbhai M, Grimshaw J, Watson M, Bond C, Mollison J, Ludbrook A. Oral versus intra-vaginal imidazole and triazole anti-fungal treatment of uncomplicated vulvovaginal candidiasis (thrush). Cochrane Database Syst Rev 2007:CD002845.
238. Sobel JD, Faro S, Force RW, et al. Vulvovaginal candidiasis: epidemiologic, diagnostic, and therapeutic considerations. Am J Obstet Gynecol. 1998;178:203-11.
239. Sobel JD, Kapernick PS, Zervos M, et al. Treatment of complicated Candida vaginitis: comparison of single and sequential doses of fluconazole. Am J Obstet Gynecol. 2001;185:363-9.
240. Sobel JD, Chaim W, Nagappan V, Leaman D. Treatment of vaginitis caused by Candida glabrata: use of topical boric acid and flucytosine. Am J Obstet Gynecol. 2003;189:1297-300.
241. Schuman P, Sobel JD, Ohmit SE, et al. Mucosal candidal colonization and candidiasis in women with or at risk for human immunodeficiency virus infection. HIV Epidemiology Research Study (HERS) Group. Clin Infect Dis. 1998;27:1161-7.
242. Rhoads JL, Wright DC, Redfield RR, Burke DS. Chronic vaginal candidiasis in women with human immunodeficiency virus infection. JAMA. 1987;257:3105-7.
243. Duerr A, Sierra MF, Feldman J, Clarke LM, Ehrlich I, DeHovitz J. Immune compromise and prevalence of Candida vulvovaginitis in human immunodeficiency virus-infected women. Obstet Gynecol. 1997;90:252-6.
244. Sobel JD, Ohmit SE, Schuman P, et al. The evolution of Candida species and fluconazole susceptibility among oral and vaginal isolates recovered from human immunodeficiency virus (HIV)- seropositive and at-risk HIV-seronegative women. J Infect Dis. 2001;183:286-93.
245. White MH. Is vulvovaginal candidiasis an AIDS-related illness? Clin Infect Dis. 1996;22 Suppl 2:S124-7.
246. Sobel JD, Wiesenfeld HC, Martens M, et al. Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. N Engl J Med. 2004;351:876-83.
247. Rex JH, Walsh TJ, Sobel JD, et al. Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America. Clin Infect Dis. 2000;30:662-78.
248. Hay RJ, Clayton YM. Fluconazole in the management of patients with chronic mucocutaneous candidosis. Br J Dermatol. 1988;119:683-4.
249. Burke WA. Use of itraconazole in a patient with chronic mucocutaneous candidiasis. J Am Acad Dermatol. 1989;21:1309-10.
250. Aiuti F, Businco L, Gatti RA. Reconstitution of T-cell disorders following thymus transplantation. Birth Defects Orig Artic Ser. 1975;11:370-6.
251. Kirkpatrick CH, Rich RR, Graw Jr. RG, Smith TK, Mickenberg I, Rogentine GN. Treatment of chronic mucocutaneous moniliasis by immunologic reconstitution. Clin Exp Immunol. 1971;9:733-48.
252. Hoh MC, Lin HP, Chan LL, Lam SK. Successful allogeneic bone marrow transplantation in severe chronic mucocutaneous candidiasis syndrome. Bone Marrow Transplant. 1996;18:797-800.
253. Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: A potential risk factor for hospital mortality. Antimicrob Agents Chemother. 2005;49:3640-5.
254. Garey KW, Rege M, Pai MP, et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: A multi-institutional study. Clin Infect Dis. 2006;43:25-31.
255. Rex JH, Bennett JE, Sugar AM, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N Engl J Med. 1994;331:1325-30.
256. Nguyen MH, Peacock Jr. JE, Tanner DC, et al. Therapeutic approaches in patients with candidemia. Evaluation in a multicenter, prospective, observational study. Arch Intern Med. 1995;155:2429-35.
257. Luzzati R, Amalfitano G, Lazzarini L, et al. Nosocomial candidemia in non-neutropenic patients at an Italian tertiary care hospital. Eur J Clin Microbiol Infect Dis. 2000;19:602-7.
258. Klein JJ, Watanakunakorn C. Hospital-acquired fungemia. Its natural course and clinical significance. Am J Med. 1979; 67:51-8.
259. Edwards Jr. JE, Bodey GP, Bowden RA, et al. International conference for the development of a consensus on the management and prevention of severe candidal infections. Clin Infect Dis. 1997;25:43-59.
260. Meunier F. Management of candidemia. N Engl J Med. 1994;331:1371-2.
261. Phillips P, Shafran S, Garber G, et al. Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients. Canadian Candidemia Study Group. Eur J Clin Microbiol Infect Dis. 1997;16:337-45.
262. Anaissie EJ, Vartivarian SE, Abi-Said D, et al. Fluconazole versus amphotericin B in the treatment of hematogenous candidiasis: A matched cohort study. Am J Med. 1996;101:170-6.
263. Rex JH, Pappas PG, Karchmer AW, et al. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis. 2003;36:1221-8.
264. Reboli AC, Rotstein C, Pappas PG, et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med. 2007; 356:2472-82.
265. Kullberg BJ, Sobel JD, Ruhnke M, et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: A randomised non-inferiority trial. Lancet. 2005;366:1435-42.
266. Kuse ER, Chetchotisakd P, da Cunha CA, et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: A phase III randomised double-blind trial. Lancet. 2007; 369:1519-27.
267. Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med. 2002;347:2020-9.
268. Bennett JE. Echinocandins for candidemia in adults without neutropenia. N Engl J Med. 2006;355:1154-9.
269. Nucci M, Colombo AL. Risk factors for breakthrough candidemia. Eur J Clin Microbiol Infect Dis. 2002;21:209-11.
270. Goldman M, Pottage Jr. JC, Weaver DC. Candida krusei fungemia. Report of 4 cases and review of the literature. Medicine (Baltimore). 1993;72:143-50.
271. Betts R, Glasmacher A, Maertens J, et al. Efficacy of caspofungin against invasive Candida or invasive Aspergillus infections in neutropenic patients. Cancer. 2006;106:466-73.
272. Blumberg EA, Reboli AC. Failure of systemic empirical treatment with amphotericin B to prevent candidemia in neutropenic patients with cancer. Clin Infect Dis. 1996;22:462-6.
273. Uzun O, Ascioglu S, Anaissie EJ, Rex JH. Risk factors and predictors of outcome in patients with cancer and breakthrough candidemia. Clin Infect Dis. 2001;32:1713-7.
274. Arnow PM, Kushner R. Malassezia furfur catheter infection cured with antibiotic lock therapy. Am J Med. 1991;90:128-30.
275. Viale P, Petrosillo N, Signorini L, Puoti M, Carosi G. Should lock therapy always be avoided for central venous catheter-associated fungal bloodstream infections? Clin Infect Dis. 2001;33:1947-8.
276. Haron E, Feld R, Tuffnell P, Patterson B, Hasselback R, Matlow A. Hepatic candidiasis: An increasing problem in immunocompromised patients. Am J Med. 1987;83:17-26.
277. Kontoyiannis DP, Luna MA, Samuels BI, Bodey GP. Hepatosplenic candidiasis. A manifestation of chronic disseminated candidiasis. Infect Dis Clin North Am. 2000;14:721-39.
278. Anaissie E, Bodey GP, Kantarjian H, et al. Fluconazole therapy for chronic disseminated candidiasis in patients with leukemia and prior amphotericin B therapy. Am J Med. 1991;91:142-50.
279. Kauffman CA, Bradley SF, Ross SC, Weber DR. Hepatosplenic candidiasis: Successful treatment with fluconazole. Am J Med. 1991;91:137-41.
280. Walsh TJ, Whitcomb PO, Revankar SG, Pizzo PA. Successful treatment of hepatosplenic candidiasis through repeated cycles of chemotherapy and neutropenia. Cancer. 1995;76:2357-62.
281. Sora F, Chiusolo P, Piccirillo N, et al. Successful treatment with caspofungin of hepatosplenic candidiasis resistant to liposomal amphotericin B. Clin Infect Dis. 2002;35:1135-6.
282. Hubel K, Chemnitz J, Brochhagen HG, Cornely OA. Successful treatment of chronic disseminated candidiasis with caspofungin and itraconazole in a patient with progressive acute leukemia and prolonged neutropenia. Int J Hematol. 2004;79:289-92.
283. Legrand F, Lecuit M, Dupont B, et al. Adjuvant corticosteroid therapy for chronic disseminated candidiasis. Clin Infect Dis. 2008;46:696-702.
284. Benjamin Jr. DK, Stoll BJ, Fanaroff AA, et al. Neonatal candidiasis among extremely low birth weight infants: risk factors, mortality rates, and neurodevelopmental outcomes at 18 to 22 months. Pediatrics. 2006;117:84-92.
285. Baley JE, Meyers C, Kliegman RM, Jacobs MR, Blumer JL. Pharmacokinetics, outcome of treatment, and toxic effects of amphotericin B and 5-fluorocytosine in neonates. J Pediatr. 1990;116:791-7.
286. Viscoli C, Castagnola E, Fioredda F, Ciravegna B, Barigione G, Terragna A. Fluconazole in the treatment of candidiasis in immunocompromised children. Antimicrob Agents Chemother. 1991;35:365-7.
287. Driessen M, Ellis JB, Cooper PA, et al. Fluconazole vs. amphotericin B for the treatment of neonatal fungal septicemia: A prospective randomized trial. Pediatr Infect Dis J. 1996;15:1107-12.
288. Wainer S, Cooper PA, Gouws H, Akierman A. Prospective study of fluconazole therapy in systemic neonatal fungal infection. Pediatr Infect Dis J. 1997;16:763-7.
289. Huang YC, Lin TY, Lien RI, et al. Candidaemia in special care nurseries: comparison of albicans and parapsilosis infection. J Infect. 2000;40:171-5.
290. Ang BS, Telenti A, King B, Steckelberg JM, Wilson WR. Candidemia from a urinary tract source: Microbiological aspects and clinical significance. Clin Infect Dis. 1993;17:662-6.
291. Coullioud D, VanderAuwera P, Viot M, Lasset C. Prospective multicentric study of the etiology of 1051 bacteremic episodes in 782 cancer patients. CEMIC (French-Belgian Study Club of Infectious Diseases in Cancer). Support Care Cancer. 1993;1:34-46.
292. Simpson C, Blitz S, Shafran SD. The effect of current management on morbidity and mortality in hospitalised adults with funguria. J Infect. 2004;49:248-52.
293. Fan-Havard P, O'Donovan C, Smith SM, Oh J, Bamberger M, Eng RH. Oral fluconazole versus amphotericin B bladder irrigation for treatment of candidal funguria. Clin Infect Dis. 1995;21:960-5.
294. Sanford JP. The enigma of candiduria: evolution of bladder irrigation with amphotericin B for management-from Anecdote to Dogma and a lesson from Machiavelli. Clin Infect Dis. 1993;16:145-7.
295. Leu HS, Huang CT. Clearance of funguria with short-course antifungal regimens: A prospective, randomized, controlled study. Clin Infect Dis. 1995;20:1152-7.
296. Wong-Beringer A, Jacobs RA, Guglielmo BJ. Treatment of funguria. JAMA. 1992;267:2780-5.
297. Albano L, Bretagne S, Mamzer-Bruneel MF, et al. Evidence that graft-site candidiasis after kidney transplantation is acquired during organ recovery: A multicenter study in France. Clin Infect Dis. 2009;48:194-202.
298. Shah CP, McKey J, Spirn MJ, Maguire J. Ocular candidiasis: A review. Br J Ophthalmol. 2008;92:466-8.
299. Martinez-Vazquez C, Fernandez-Ulloa J, Bordon J, et al. Candida albicans endophthalmitis in brown heroin addicts: response to early vitrectomy preceded and followed by antifungal therapy. Clin Infect Dis. 1998;27:1130-3.
300. Results of the Endophthalmitis Vitrectomy Study. A randomized trial of immediate vitrectomy and of intravenous antibiotics for the treatment of postoperative bacterial endophthalmitis Endophthalmitis Vitrectomy Study Group. Arch Ophthalmol 1995;113:1479-96.
301. Stern GA, Fetkenhour CL, O'Grady RB. Intravitreal amphotericin B treatment of Candida endophthamitis. Arch Ophthalmol. 1977;95:89-93.
302. Perraut Jr. LE, Perraut LE, Bleiman B, Lyons J. Successful treatment of Candida albicans endophthalmitis with intravitreal amphotericin B. Arch Ophthalmol. 1981;99:1565-7.
303. Brod RD, Flynn Jr. HW, Clarkson JG, Pflugfelder SC, Culbertson WW, Miller D. Endogenous Candida endophthalmitis. Management without intravenous amphotericin B. Ophthalmology. 1990;97:666-72. disc: 72-4.
304. Savani DV, Perfect JR, Cobo LM, Durack DT. Penetration of new azole compounds into the eye and efficacy in experimental Candida endophthalmitis. Antimicrob Agents Chemother. 1987;31:6-10.
305. O'Day DM, Foulds G, Williams TE, Robinson RD, Allen RH, Head WS. Ocular uptake of fluconazole following oral administration. Arch Ophthalmol. 1990;108:1006-8.
306. Urbak SF, Degn T. Fluconazole in the treatment of Candida albicans endophthalmitis. Acta Ophthalmol (Copenh). 1992;70:528-9.
307. Akler ME, Vellend H, McNeely DM, Walmsley SL, Gold WL. Use of fluconazole in the treatment of candidal endophthalmitis. Clin Infect Dis. 1995;20:657-64.
308. Kauffman CA, Bradley SF, Vine AK. Candida endophthalmitis associated with intraocular lens implantation: efficacy of fluconazole therapy. Mycoses. 1993;36:13-7.
309. Zenker PN, Rosenberg EM, VanDyke RB, Rabalais GP, Daum RS. Successful medical treatment of presumed Candida endocarditis in critically ill infants. J Pediatr. 1991;119:472-7.
310. Faix RG. Nonsurgical treatment of Candida endocarditis. J Pediatr. 1992;120:665-6.
311. Melamed R, Leibovitz E, Abramson O, Levitas A, Zucker N, Gorodisher R. Successful non-surgical treatment of Candida tropicalis endocarditis with liposomal amphotericin-B (AmBisome). Scand J Infect Dis. 2000;32:86-9.
312. Aaron L, Therby A, Viard JP, Lahoulou R, Dupont B. Successful medical treatment of Candida albicans in mechanical prosthetic valve endocarditis. Scand J Infect Dis. 2003;35:351-2.
313. Utley JR, Mills J, Roe BB. The role of valve replacement in the treatment of fungal endocarditis. J Thorac Cardiovasc Surg. 1975;69:255-8.
314. Nguyen MH, Nguyen ML, Yu VL, McMahon D, Keys TF, Amidi M. Candida prosthetic valve endocarditis: Prospective study of six cases and review of the literature. Clin Infect Dis. 1996;22:262-7.
315. Muehrcke DD. Fungal prosthetic valve endocarditis. Semin Thorac Cardiovasc Surg. 1995;7:20-4.
316. Muehrcke DD, Lytle BW, Cosgrove 3rd DM. Surgical and longterm antifungal therapy for fungal prosthetic valve endocarditis. Ann Thorac Surg. 1995;60:538-43.
317. Jimenez-Exposito MJ, Torres G, Baraldes A, et al. Native valve endocarditis due to Candida glabrata treated without valvular replacement: A potential role for caspofungin in the induction and maintenance treatment. Clin Infect Dis. 2004;39:e70-3.
318. Rajendram R, Alp NJ, Mitchell AR, Bowler IC, Forfar JC. Candida prosthetic valve endocarditis cured by caspofungin therapy without valve replacement. Clin Infect Dis. 2005;40:e72-4.
319. Moudgal V, Little T, Boikov D, Vazquez JA. Multiechinocandinand multiazole-resistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis. Antimicrob Agents Chemother. 2005;49:767-9.
320. Cancelas JA, Lopez J, Cabezudo E, et al. Native valve endocarditis due to Candida parapsilosis: A late complication after bone marrow transplantation-related fungemia. Bone Marrow Transplant. 1994;13:333-4.
321. Mayayo E, Moralejo J, Camps J, Guarro J. Fungal endocarditis in premature infants: case report and review. Clin Infect Dis. 1996;22:366-8.
322. Johnston PG, Lee J, Domanski M, et al. Late recurrent Candida endocarditis. Chest. 1991;99:1531-3.
323. Roupie E, Darmon JY, Brochard L, Saada M, Rekik N, Brun- Buisson C. Fluconazole therapy of candidal native valve endocarditis. Eur J Clin Microbiol Infect Dis. 1991;10:458-9.
324. Hernandez JA, Gonzalez-Moreno M, Llibre JM, Aloy A, Casan CM. Candidal mitral endocarditis and long-term treatment with fluconazole in a patient with human immunodeficiency virus infection. Clin Infect Dis. 1992;15:1062-3.
325. Castiglia M, Smego Jr. RA, Sames EL. Candida endocarditis and amphotericin B intolerance: Potential role for fluconazole. Infect Dis Clin Pract. 1994;3:248-53.
326. Baddley JW, Benjamin Jr. DK, Patel M, et al. Candida infective endocarditis. Eur J Clin Microbiol Infect Dis. 2008;27:519-29.
327. Steinbach WJ. Antifungal agents in children. Pediatr Clin North Am. 2005;52:895-915.
328. Rabinovici R, Szewczyk D, Ovadia P, Greenspan JR, Sivalingam JJ. Candida pericarditis: clinical profile and treatment. Ann Thorac Surg. 1997;63:1200-4.
329. Torres-Rojas JR, Stratton CW, Sanders CV, et al. Candidal suppurative peripheral thrombophlebitis. Ann Intern Med. 1982;96:431-5.
330. Jarrett F, Maki DG, Chan CK. Management of septic thrombosis of the inferior vena cava caused by Candida. Arch Surg. 1978;113:637-9.
331. Strinden WD, Helgerson RB, Maki DG. Candida septic thrombosis of the great central veins associated with central catheters. Clinical features and management. Ann Surg. 1985;202:653-8.
332. Montenegro J, Aguirre R, Gonzalez O, Martinez I, Saracho R. Fluconazole treatment of candida peritonitis with delayed removal of the peritoneal dialysis catheter. Clin Nephrol. 1995;44:60-3.
333. Michel C, Courdavault L, al Khayat R, Viron B, Roux P, Mignon F. Fungal peritonitis in patients on peritoneal dialysis. Am J Nephrol. 1994;14:113-20.
334. Bayer AS, Blumenkrantz MJ, Montgomerie JZ, Galpin JE, Coburn JW, Guze LB. Candida peritonitis. Report of 22 cases and review of the English literature. Am J Med. 1976;61:832-40.
335. Sugar AM. Antifungal therapy in CAPD peritonitis-do we have a choice? Semin Dial. 1991;4:145-6.
336. Arfania D, Everett ED, Nolph KD, Rubin J. Uncommon causes of peritonitis in patients undergoing peritoneal dialysis. Arch Intern Med. 1981;141:61-4.
337. Levine J, Bernard DB, Idelson BA, Farnham H, Saunders C, Sugar AM. Fungal peritonitis complicating continuous ambulatory peritoneal dialysis: Successful treatment with fluconazole, a new orally active antifungal agent. Am J Med. 1989;86:825-7.
338. Corbella X, Sirvent JM, Carratala J. Fluconazole treatment without catheter removal in Candida albicans peritonitis complicating peritoneal dialysis. Am J Med. 1991;90:277.
339. Eisenberg ES. Intraperitoneal flucytosine in the management of fungal peritonitis in patients on continuous ambulatory peritoneal dialysis. Am J Kidney Dis. 1988;11:465-7.
340. Solomkin JS, Simmons RL. Candida infection in surgical patients. World J Surg. 1980;4:381-94.
341. Solomkin JS, Flohr AB, Quie PG, Simmons RL. The role of Candida in intraperitoneal infections. Surgery. 1980;88:524-30.
342. Alden SM, Frank E, Flancbaum L. Abdominal candidiasis in surgical patients. Am Surg. 1989;55:45-9.
343. Rantala A, Lehtonen OP, Kuttila K, Havia T, Niinikoski J. Diagnostic factors for postoperative candidosis in abdominal surgery. Ann Chir Gynaecol. 1991;80:323-8.
344. Aguado JM, Hidalgo M, Ridriguez-Tudela JL. Successful treatment of candida peritonitis with fluconazole. J Antimicrob Chemother. 1994;34:847.
345. Adamson PC, Rinaldi MG, Pizzo PA, Walsh TJ. Amphotericin B in the treatment of Candida cholecystitis. Pediatr Infect Dis J. 1989;8:408-11.
346. Hoerauf A, Hammer S, Muller-Myhsok B, Rupprecht H. Intraabdominal Candida infection during acute necrotizing pancreatitis has a high prevalence and is associated with increased mortality. Crit Care Med. 1998;26:2010-5.
347. Grewe M, Tsiotos GG, Luque de-Leon E. Sarr MG. Fungal infection in acute necrotizing pancreatitis. J Am Coll Surg. 1999;188:408-14.
348. Gathe Jr. JC, Harris RL, Garland B, Bradshaw MW, Williams Jr. TW. Candida osteomyelitis. Report of five cases and review of the literature. Am J Med. 1987;82:927-37.
349. Ferra C, Doebbeling BN, Hollis RJ, Pfaller MA, Lee CK, Gingrich RD. Candida tropicalis vertebral osteomyelitis: A late sequela of fungemia. Clin Infect Dis. 1994;19:697-703.
350. Almekinders LC, Greene WB. Vertebral Candida infections. A case report and review of the literature. Clin Orthop Relat Res 1991:174-8.
351. Marra F, Robbins GM, Masri BA, et al. Amphotericin B-loaded bone cement to treat osteomyelitis caused by Candida albicans. Can J Surg. 2001;44:383-6.
352. Sugar AM, Saunders C, Diamond RD. Successful treatment of Candida osteomyelitis with fluconazole. A noncomparative study of two patients. Diagn Microbiol Infect Dis. 1990;13:517-20.
353. Bannatyne RM, Clarke HM. Ketoconazole in the treatment of osteomyelitis due to Candida albicans. Can J Surg. 1989;32:201-2.
354. Hennequin C, Bouree P, Hiesse C, Dupont B, Charpentier B. Spondylodiskitis due to Candida albicans: report of two patients who were successfully treated with fluconazole and review of the literature. Clin Infect Dis. 1996;23:176-8.
355. Dan M, Priel I. Failure of fluconazole therapy for sternal osteomyelitis due to Candida albicans. Clin Infect Dis. 1994;18:126-7.
356. Arranz-Caso JA, Lopez-Pizarro VM, Gomez-Herruz P, Garcia- Altozano J, Martinez-Martinez J. Candida albicans osteomyelitis of the zygomatic bone. A distinctive case with a possible peculiar mechanism of infection and therapeutic failure with fluconazole. Diagn Microbiol Infect Dis. 1996;24:161-4.
357. Tunkel AR, Thomas CY, Wispelwey B. Candida prosthetic arthritis: report of a case treated with fluconazole and review of the literature. Am J Med. 1993;94:100-3.
358. Merrer J, Dupont B, Nieszkowska A, De Jonghe B, Outin H. Candida albicans prosthetic arthritis treated with fluconazole alone. J Infect. 2001;42:208-9.
359. Bayer AS, Guze LB. Fungal arthritis. I. Candida arthritis: diagnostic and prognostic implications and therapeutic considerations. Semin Arthritis Rheum. 1978;8:142-50.
360. Katzenstein D. Isolated Candida arthritis: report of a case and definition of a distinct clinical syndrome. Arthritis Rheum. 1985;28:1421-4.
361. Weers-Pothoff G, Havermans JF, Kamphuis J, Sinnige HA, Meis JF. Candida tropicalis arthritis in a patient with acute myeloid leukemia successfully treated with fluconazole: case report and review of the literature. Infection. 1997;25:109-11.
362. Smego Jr. RA, Perfect JR, Durack DT. Combined therapy with amphotericin B and 5-fluorocytosine for Candida meningitis. Rev Infect Dis. 1984;6:791-801.
363. Buchs S, Pfister P. Candida meningitis. Course, prognosis and mortality before and after introduction of the new antimycotics. Mykosen. 1983;26:73-81.
364. Marr B, Gross S, Cunningham C, Weiner L. Candidal sepsis and meningitis in a very-low-birth-weight infant successfully treated with fluconazole and flucytosine. Clin Infect Dis. 1994;19:795-6.
365. Gurses N, Kalayci AG. Fluconazole monotherapy for candidal meningitis in a premature infant. Clin Infect Dis. 1996;23:645-6.
366. Chiou CC, Wong TT, Lin HH, et al. Fungal infection of ventriculoperitoneal shunts in children. Clin Infect Dis. 1994;19:1049-53.
367. Cruciani M, Di Perri G, Molesini M, Vento S, Concia E, Bassetti D. Use of fluconazole in the treatment of Candida albicans hydrocephalus shunt infection. Eur J Clin Microbiol Infect Dis. 1992;11:957.
368. Black JT. Cerebral candidiasis: case report of brain abscess secondary to Candida albicans, and review of literature. J Neurol Neurosurg Psychiatry. 1970;33:864-70.
369. Bonomo RA, Strauss M, Blinkhorn R, Salata RA. Torulopsis (Candida) glabrata: A new pathogen found in spinal epidural abscess. Clin Infect Dis. 1996;22:588-9.
370. Lutsar I, Roffey S, Troke P. Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised patients. Clin Infect Dis. 2003;37:728-32.
371. Liu KH, Wu CJ, Chou CH, et al. Refractory candidal meningitis in an immunocompromised patient cured by caspofungin. J Clin Microbiol. 2004;42:5950-3.
372. Hope WW, Mickiene D, Petraitis V, et al. The pharmacokinetics and pharmacodynamics of micafungin in experimental hematogenous Candida meningoencephalitis: Implications for echinocandin therapy in neonates. J Infect Dis. 2008;197:163-71.
373. Rangel-Frausto MS, Wiblin T, Blumberg HM, et al. National epidemiology of mycoses survey (NEMIS): variations in rates of bloodstream infections due to Candida species in seven surgical intensive care units and six neonatal intensive care units. Clin Infect Dis. 1999;29:253-8.
374. Garbino T, Lew D, Romand JA. Fluconazole prevents severe Candida spp. infections in high risk critically ill patients. In: Paper presented at the American Society Microbiology. Washington, DC; 1997.
375. Rocco TR, Simms HH. Inadequate proof of adverse outcome due to the use of fluconazole in critically ill patients. Arch Surg. 2000;135:1114.
376. Gleason TG, May AK, Caparelli D, Farr BM, Sawyer RG. Emerging evidence of selection of fluconazole-tolerant fungi in surgical intensive care units. Arch Surg. 1997;132:1197-201. discussion 202.
377. Savino JA, Agarwal N, Wry P, Policastro A, Cerabona T, Austria L. Routine prophylactic antifungal agents (clotrimazole, ketoconazole, and nystatin) in nontransplant/nonburned critically ill surgical and trauma patients. J Trauma. 1994;36:20-5. discussion 5-6.
378. Ables AZ, Blumer NA, Valainis GT, Godenick MT, Kajdasz DK, Yuko Y. Fluconazole prophylaxis of severe candida infection in trauma and postsurgical patients: A prospective, double-blind, randomized, placebo-controlled trial. Infect Dis Clin Pract. 2000;9:169-75.
379. Schuster MG, Edwards Jr. JE, Sobel JD, et al. Empirical fluconazole versus placebo for intensive care unit patients: A randomized trial. Ann Intern Med. 2008;149:83-90.
380. Pelz RK, Hendrix CW, Swoboda SM, et al. Double-blind placebocontrolled trial of fluconazole to prevent candidal infections in critically ill surgical patients. Ann Surg. 2001;233:542-8.
381. Piarroux R, Grenouillet F, Balvay P, et al. Assessment of preemptive treatment to prevent severe candidiasis in critically ill surgical patients. Crit Care Med. 2004;32:2443-9.
382. Kung N, Fisher N, Gunson B, Hastings M, Mutimer D. Fluconazole prophylaxis for high-risk liver transplant recipients. Lancet. 1995;345:1234-5.
383. Tollemar J, Hockerstedt K, Ericzon BG, Jalanko H, Ringden O. Liposomal amphotericin B prevents invasive fungal infections in liver transplant recipients. A randomized, placebo-controlled study. Transplantation. 1995;59:45-50.
384. Ostrosky-Zeichner L, Sable C, Sobel J, et al. Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting. Eur J Clin Microbiol Infect Dis. 2007;26:271-6.
385. Kaufman D, Boyle R, Hazen KC, Patrie JT, Robinson M, Donowitz LG. Fluconazole prophylaxis against fungal colonization and infection in preterm infants. N Engl J Med. 2001;345:1660-6.
386. Manzoni P, Stolfi I, Pugni L, et al. A multicenter, randomized trial of prophylactic fluconazole in preterm neonates. N Engl J Med. 2007;356:2483-95.